Home > Result Summaries: Compounds > valaciclovir Result Summaries: valaciclovir GSKStudy ID Phase Title Summary (Download) 100181 Phase 4 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. (0 citation(s)) 100273 Phase 4 A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes (0 citation(s)) 101735 phase 1 A pharmacokinetic study to evaluate the intra-ocular penetration of aciclovir following single, oral dose of valaciclovir in subjects undergoing cataract surgery (0 citation(s)) 104689 Phase 4 Post-Marketing Clinical Study of Valaciclovir Hydrochloride Tablets -Single Oral Dose Study in Hemodialysis Patients- (0 citation(s)) 112315 N/A Drug Use Investigation for Valtrex (zoster herpes) (0 citation(s)) 112317 N/A Special Drug Use Investigation for Valtrex (postherpetic neuralgia) (0 citation(s)) 112319 phase 4 Special Drug Use Investigation for VALTREX (Valaciclovir) (suppression prophylaxis) (1 citation(s)) 112323 phase 4 Special Drug Use Investigation for VALTREX (valaciclovir) (Pediatrics Chickenpox) (0 citation(s)) 112327 phase 4 Special Drug Use Investigation for Valtrex (Adult Chickenpox) (0 citation(s)) 113849 N/A Recruitment and safety of Valtrex in HIV+ patients with CD4 < 100 (0 citation(s)) 123(H73)-013-V Phase 1 The Pharmacokinetics of Valaciclovir and Acyclovir After Oral Administration of a Single Dose of Valaciclovir to Patients With Cirrhosis and Healthy Volunteers (0 citation(s)) 123-007 Phase 3 A Comparative Trial of Valaciclovir and Aciclovir for the Suppression of Ano-Genital Herpes Infections in HIV-Infected Patients (2 citation(s)) 123-008 Phase 3 A Study to Investigate the Efficacy and Safety of Valaciclovir in the Treatment of Recurrent Ano-Genital Herpes in HIV-Infected Patients (2 citation(s)) 123-014 Phase 3 A Randomised Double-Blind Trial of Valaciclovir (BW256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (&lt;100CD4+ Lymphocytes) (1 citation(s)) 123-016 Phase 3 123-016: A Double-blind, Multi-centre Study Comparing Oral Valaciclovir and Aciclovir for the Suppression of CMV Infection and Disease Following Allogeneic Bone Marrow Transplantation (1 citation(s)) 123-026 Phase 3 A Comparative Trial of Valaciclovir With Aciclovir and Placebo for the Suppression of Recurrent Genital Herpes Infections in Immunocompetent Patients (1 citation(s)) 123-031 Phase 2 A Pilot, Randomized, Double-Blind Study to Investigate the use of Valaciclovir for the Prophylaxis of CMV Infection in Recipients of a Heart or Single Lung Transplant (1 citation(s)) 123-033 Phase 3 A randomized, double blind, placebo controlled cross over trial to compare valacyclovir HCl and acyclovir for suppression of subclinical herpes simplex virus sheddingExtensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) 123-034 Phase 1 Report of the Pharmacokinetics of Aciclovir and Digoxin Following Administration of Digoxin and Valaciclovir Alone and in Combination to Healthy Volunteers (2 citation(s)) 123-037 Phase 3 A Randomised, Double-Blind, Controlled Study of Valaciclovir for the Suppression of Recurrent Genital Herpes Simplex Virus Infection in Immunocompetent Patients (1 citation(s)) 123-038 Phase 1 Evaluation of the Effect of an Aluminium Hydroxide and Magnesium Hydroxide Containing Antacid on the Pharmacokinetics of Valaciclovir and Acyclovir Following a Single Oral Dose of Valaciclovir (1 citation(s)) 123-044 Phase 3 Pharmacokinetics of valaciclovir in late pregnancy (1 citation(s)) 123-304 Phase 3 Zoster ophthalmicus in immunocompetent patientsExtensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication. See citation below. (1 citation(s)) 123-310 Phase 3 A double-blind, multicenter study comparing valacyclovir HCL with famciclovir for the treatment of uncomplicated herpes zoster in immunocompetent patients 50 years of age and olderExtensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) H73-020-V Phase 1 The Effects of Probenecid and Cimetidine on the Pharmacokinetics of Valaciclovir and its Metabolite Acyclovir in Healthy Male Volunteers (2 citation(s)) HS2100275 phase 4 An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6- Month Study of the Efficacy and Safety of Valaciclovir 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Subjects (0 citation(s)) HS2101951 phase 3 Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients with Chickenpox - Open Uncontrolled Study. (0 citation(s)) HS210909 Phase 1 Report of a Study to Evaluate the Bioequivalence of Single Doses of an Investigational Formulation of Valaciclovir Compared to the Standard Valaciclovir Tablet in Healthy Volunteers (0 citation(s)) HS210911 Phase 1 A Randomised, Open-Label, Cross-Over, Single Dose Study to Evaluate the Pharmacokinetic Interaction Between Aciclovir 800mg and Mycophenolate Mofetil 1000mg and Between Valaciclovir 2000mg and Mycophenolate Mofetil 1000mg in Healthy Volunteers (2 citation(s)) HS210914 phase 1 An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children. (2 citation(s)) HS210915 Phase 1 An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection (2 citation(s)) HS210916 Phase 1 An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection (2 citation(s)) HS230017 Phase 3 An open-label, randomized, crossover study to determine subject treatment preference and efficacy of once daily valacyclovir 500 mg suppression therapy versus valacyclovir 500 mg twice daily treatment for recurrent genital HSV infections. (1 citation(s)) HS230018 Phase 3 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects (2 citation(s)) HS230027 Phase 3 A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes (2 citation(s)) HS230028 Phase 3 A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development (2 citation(s)) HS240016 Phase 1 CSF Penetration of Acyclovir and its Metabolites After High Dose Valacyclovir Administration (2 citation(s)) HS240017 Phase 4 A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes (0 citation(s)) HS240018 Phase 4 A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes (0 citation(s)) HS240021 Phase 4 A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes (0 citation(s)) HS2A3005 Phase 3 An Open-Label, Pilot Study to Estimate the Effect on Subject Survival and the Safety of CMV Prophylaxis with IV Acyclovir Followed by Valacyclovir Hydrochloride or Ganciclovir in Allogeneic Bone Marrow Transplant Recipients (1 citation(s)) HS2A4004 Phase 3 A Comparison of Oral VALTREX 500mg Twice Daily for Three or Five Days for Treatment of Recurrent Genital Herpes (1 citation(s)) HS2AB3009 Phase 3 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase) (1 citation(s)) HS2B1001 Phase 3 A study to compare the intraocular penetration of valaciclovir and aciclovir following multiple dose oral administration to patients undergoing cataract surgery.Extensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) HS2B3010 Phase 3 A Randomized, Double-Blind Study to Compare Valaciclovir 500mg Twice Daily Given for Three Days With the Standard Five Day Course as Episodic Treatment for Recurrent Genital Herpes (1 citation(s)) HS2B4001 Phase 1 A Pharmacokinetic Study to Compare Aciclovir Plasma Exposures Attained with IV Zovirax® 5mg/kg t.d.s and Oral Valtrex® 1000mg t.d.s. in Neutropenic Non-HIV Patients (1 citation(s)) HS2B4005 Phase 1 An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children (1 citation(s)) HSV-003(JP) Phase 3 Phase III Study of Valaciclovir Hydrochloride Tablets in Immunocompetent Patients With Herpes Simplex Virus Infections – Double-Blind Comparative With Aciclovir Tablets (1 citation(s)) P66/H73-005 Phase 3 An International, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 50 Years of Age or Older (2 citation(s)) P66/H73-006 Phase 3 A Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients Less Than 50 Years Old (0 citation(s)) P66/H73-012 Phase 3 Pharmacokinetic Analysis: Oral 256U87 Safety, Pharmacokinetics, and Prophylaxis of Cytomegalovirus Infection and Disease in Renal Allograft Recipients (2 citation(s)) P66/H73-012 (CMV Seronegative Recipients) Phase 3 Oral 256U87 (Valaciclovir) Safety, Pharmacokinetics and Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients (1 citation(s)) P66/H73-012 (CMV Seropositive Recipients) Phase 3 Oral 256U87 (Valaciclovir) Safety, Pharmacokinetics and Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients (1 citation(s)) P66-09 (123-009) Phase 1 Single-Dose Pharmacokinetics and Safety of Valaciclovir in Volunteers with End-Stage Renal Disease (0 citation(s)) P66-10 Phase 1 Pharmacokinetics and Safety of Acyclovir and Valaciclovir Following Single and Multiple Oral Administration of Valaciclovir in Geriatric Volunteers With and Without Concomitant Diuretic Therapy (2 citation(s)) P66-H73-003 Phase 3 A Comparative Trial of Valacyclovir and Acyclovir for the Treatment of First-Episode Genital Herpes Infection (1 citation(s)) PREV123 Phase 4 Multicentre randomised trial comparing two strategies for the episodic use of valaciclovir, alone or combined with suppressive treatment in immunocompetent patients with recurrent genital herpes (0 citation(s)) U87TH-04 Phase 3 Clinical Effect of Valaciclovir Hydrochloride (256U87) Tablets in Patients With Genital Herpes (1 citation(s)) VAL R24 Phase 4 A Double-Blind Study Comparing Two Doses of Valacyclovir HCL for the Treatment of Uncomplicated Herpes Zoster in Immunocompromised Patients 18 Years of Age and Older (0 citation(s)) VALF1004 Phase 1 Safety Follow-Up of the Association Valaciclovir –Tacrolimus and Evaluation of the Potential Pharmacokinetic Interaction Between Valaciclovir and Tacrolimus When They are Co-Administered in Renal Transplant Recipients (0 citation(s)) VALF1005 Phase 4 Safety Follow-Up of the Association Valaciclovir-Mycophenolate Mofetil and Evaluation of the Potential Pharmacokinetic Interaction Between Valaciclovir and Mycophenolate Mofetil When They are Co-Administered in Renal Transplant Recipients (0 citation(s)) VALF1007 Phase 4 A pharmacokinetic study to evaluate the intra-ocular penetration of aciclovir following single, oral dose of valaciclovir in subjects undergoing cataract surgery. (0 citation(s)) VALF3002 Phase 3 Multicentre, randomised, open-label study to compare the efficacy and safety of valaciclovir oral route and aciclovir intravenous route, to treat zoster in immunodeficient patients. (1 citation(s)) VAL-R19 Phase 3 A Single-Center, Open-Label Study of the Safety and Pharmacokinetics of Valacyclovir in Children with Epstein-Barr Virus Illness Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) VAL-R56 Phase 3 Acyclovir Concentrations in Human Breast Milk After Valaciclovir Administration. Extensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) VALR94 Phase 4 An Open-Label Pilot Study of valacyclovir (VALTREX) 2000 mg BID for One Day in the Episodic Treatment of Recurrent Genital Herpes (1 citation(s)) VLX103596 Phase 4 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection. (0 citation(s)) VLX105832 phase 4 The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection (0 citation(s))
